Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 285Lymphoma 201Lymphoma, Large B-Cell, Diffuse 167Sarcoma 141Precursor Cell Lymphoblastic Leukemia-Lymphoma 109Hodgkin Disease 85Lymphoma, Non-Hodgkin 78Burkitt Lymphoma 67Lymphoma, Follicular 61Leukemia 58Ovarian Neoplasms 50Neoplasms 50Triple Negative Breast Neoplasms 49Lymphoma, Mantle-Cell 48Multiple Myeloma 47Neuroblastoma 44Carcinoma, Hepatocellular 44Neoplasm Metastasis 41Lymphoma, B-Cell 33Lymphoma, Large-Cell, Anaplastic 31Lymphoma, T-Cell, Peripheral 27Recurrence 26Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 25Osteosarcoma 25Liposarcoma 25Leiomyosarcoma 25Urinary Bladder Neoplasms 23Lymphoma, Large-Cell, Immunoblastic 23Liver Neoplasms 22Endometrial Neoplasms 21

Interventions

Dexamethasone 3iniparib 2Poly(ADP-ribose) Polymerase Inhibitors 2Calcium Dobesilate 2dexamethasone acetate 1dexamethasone 21-phosphate 1asparaginase erwinia chrysanthemi recombinant 1amminedichloro(2-methylpyridine)platinum(II) 1ZD4054 1Vincristine 1Sodium Chloride 1Rituximab 1Paclitaxel 1Narrow Band Imaging 1Methotrexate 1Doxorubicin 1Dexrazoxane 1Cytarabine 1Carboplatin 1BNT162 Vaccine 1Asparaginase 12019-nCoV Vaccine mRNA-1273 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hypersensitivity × Doxorubicin × Clear all
NCT00928200 2019-02-19

Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)

Therapeutic Advances in Childhood Leukemia Consortium

Phase 1 Terminated
1 enrolled 7 charts
LymphoidOther hematologic neoplasm

Hypersensitivity, Leukemia, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡